FOXO4-DRI Sourcing Vocabulary and Catalogue Query Orthography: A Research Review of D-Retro-Inverso Senolytic Peptide Identity, p53 Nuclear Exclusion Mechanism and Preclinical Evidence

By Peptide Insider Research Desk · October 2026 · Research-use-only reference

Researchers investigating cellular senescence encounter a broad family of catalogue labels when sourcing the peptide variously listed as fox peptide, fox04 dri peptide, fox 04, fox-04, fox 04 dri peptide, fox 4 peptide, and fox 04-dri. Each of these tokens resolves to a single compound: the D-retro-inverso senolytic peptide FOXO4-DRI, first described by Baar et al. in 2017 [1]. This review traces the structural identity behind these catalogue orthographies, examines the FOXO4–p53 interaction that the peptide disrupts, surveys the preclinical evidence base, and classifies every search variant by its Research-Use-Only (RUO) scope status. All content herein is strictly for research reference; not for human or veterinary use.

Catalogue Query Orthography and Nomenclature Resolution

Vendor databases index FOXO4-DRI under a heterogeneous set of abbreviated, truncated and hyphen-variant labels. The table below maps each search token recorded in organic keyword logs to its canonical identity and RUO scope status. Researchers querying buy foxo4-dri or buy foxo4 dri should note that these sourcing-intent labels resolve to the same investigational compound and that no regulatory agency has approved FOXO4-DRI for any therapeutic indication.

The dominant transcription error class is prefix truncation, where the gene symbol "FOXO4" is shortened to "fox" or "fox 04" by users unfamiliar with the Forkhead Box O subfamily nomenclature. The homoglyph substitution O→0 (producing "fox04") mirrors a pattern observed across peptide catalogues for gene-symbol-derived compound names [1,2].

FOXO4–p53 Interaction: The Senescence Survival Axis

Cellular senescence is a state of irreversible proliferative arrest accompanied by the senescence-associated secretory phenotype (SASP)—a pro-inflammatory programme secreting interleukins, matrix metalloproteinases and growth factors that remodel surrounding tissue [9,10]. While senescence serves a tumour-suppressive function and participates in wound repair [11], the progressive accumulation of senescent cells with age contributes to chronic inflammation, tissue dysfunction and age-related pathology [5,6,8,13].

In senescent cells, the transcription factor FOXO4 is upregulated and physically sequesters the tumour suppressor p53 within the nucleus [1]. This interaction prevents p53 from translocating to the mitochondria, where it would otherwise initiate the intrinsic apoptosis cascade [1,2]. The FOXO4–p53 complex therefore functions as a survival mechanism that protects senescent cells from programmed death, enabling their persistence and continued SASP secretion [1,8].

Structural studies using NMR spectroscopy have mapped the binding interface to the FOXO4 forkhead domain (FOXO4^FH) and the second sub-domain of the p53 transactivation domain (p53^TAD2) [2]. Phosphorylation of p53 at residues Ser46 and Thr55 significantly enhances binding affinity for both endogenous FOXO4 and the synthetic FOXO4-DRI peptide, suggesting that phospho-p53 enrichment in senescent cells contributes to the selectivity of the senolytic effect [2].

D-Retro-Inverso Engineering and Protease Resistance

Native L-peptides of 48 residues are rapidly degraded by serum proteases, limiting their experimental utility in cell-culture and animal models [12]. The D-retro-inverso (DRI) strategy addresses this limitation through two simultaneous modifications: (a) substitution of every L-amino acid with its D-enantiomer, and (b) reversal of the peptide-bond direction so that side-chain topology is preserved while the backbone becomes unrecognisable to endogenous peptidases [1,12]. Chorev (2005) reviewed the principles underlying partial and complete retro-inverso modifications, demonstrating that DRI peptides can retain target-binding geometry while exhibiting dramatically extended serum half-lives [12]. In the context of fox peptide sourcing queries, the DRI suffix is the critical structural feature distinguishing the research-grade senolytic from the endogenous FOXO4 protein itself.

Preclinical Evidence Base

Across these models, selectivity for senescent over non-senescent cells is attributed to the differential expression of the FOXO4–p53 survival complex: healthy cells maintain lower levels of this interaction and are therefore less susceptible to DRI-mediated displacement [1,2]. No human clinical trials have been registered or published for FOXO4-DRI as of October 2026; all pharmacokinetic, safety and efficacy data derive exclusively from cell-culture and murine models.

Senolytic Context: FOXO4-DRI Among Clearance Strategies

FOXO4-DRI belongs to the senolytic class of investigational compounds—agents that selectively eliminate senescent cells rather than suppressing their secretory phenotype (senomorphics) [7,8]. The first senolytic combination reported, dasatinib plus quercetin (D+Q), targets senescent-cell anti-apoptotic pathways (SCAPs) through a multi-kinase inhibition strategy [7]. Navitoclax (ABT-263) acts via BCL-2/BCL-xL inhibition. FOXO4-DRI occupies a mechanistically distinct niche: rather than broadly targeting anti-apoptotic signalling, it specifically disrupts the FOXO4–p53 protein–protein interaction that maintains nuclear p53 sequestration [1,2,8].

Baker et al. (2011, 2016) demonstrated in transgenic models that genetic clearance of p16^Ink4a-positive senescent cells delayed age-related pathology and extended median lifespan, establishing the foundational rationale for pharmacological senolytic intervention [5,6]. FOXO4-DRI represents the first peptide-based approach to achieve comparable senescent-cell clearance through targeted protein–protein interaction disruption in preclinical models [1].

Frequently Asked Questions

What is fox peptide and how does it relate to FOXO4-DRI?

The search term fox peptide is a truncated catalogue label for FOXO4-DRI, a D-retro-inverso senolytic peptide that disrupts the FOXO4–p53 interaction in senescent cells [1]. The abbreviation arises from prefix truncation of the gene symbol "FOXO4."

Is fox04 dri peptide the same compound as fox 04 dri peptide?

Yes. Fox04 dri peptide and fox 04 dri peptide are whitespace and homoglyph variants of the same compound, FOXO4-DRI. The numeral "04" corresponds to the fourth member of the Forkhead Box O transcription factor subfamily [1,2].

Where does fox-04 appear in senolytic research literature?

Fox-04 does not appear in peer-reviewed literature under that exact spelling; the canonical designation is FOXO4-DRI [1]. The hyphenated form originates from catalogue search-engine tokenisation patterns.

What distinguishes fox 4 peptide queries from fox 04 queries?

The label fox 4 peptide reflects numeral truncation (dropping the leading zero from "04"), while fox 04 retains the two-digit gene-subfamily number. Both resolve to FOXO4-DRI [1].

What does buy foxo4-dri indicate about the compound's regulatory status?

Queries such as buy foxo4-dri and buy foxo4 dri reflect sourcing intent for an investigational compound that has no regulatory approval for human or veterinary therapeutic use as of October 2026 [1,8]. All available preparations are designated for in-vitro and preclinical research applications only.

Where to Source FOXO4-DRI for Research

Investigators sourcing FOXO4-DRI for in-vitro or preclinical studies should evaluate vendor certificates of analysis (CoA) for peptide purity (≥95% by HPLC), mass-spectrometric identity confirmation (ESI-MS or MALDI-TOF), and endotoxin testing. The following suppliers maintain catalogues that include senolytic peptides for research applications:

• Short Chain Aminos — primary catalogue for FOXO4-DRI and related senolytic peptide research reagents.
• BioPep — peptide synthesis and custom sequence services for investigational compounds.
• Catalyst Research — research-grade peptide supply with third-party analytical verification.
• Apex Research Services — specialised sourcing for DRI-modified and protease-resistant peptide formats.

No vendor listed above has been assessed or endorsed by this publication; inclusion reflects catalogue availability, not quality endorsement.

Works Cited

1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PMID: 28340339.
2. Bourgeois B, Krivak D, Rabl L, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16:5673. PMID: 40593617.
3. Kong YX, Lu JJ, Zheng MJ, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of p53. Commun Biol. 2025;8:291. PMID: 39994346.
4. Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284. PMID: 31959736.
5. Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184-189. PMID: 26840489.
6. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232-236. PMID: 22048312.
7. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. PMID: 25754370.
8. Childs BG, Gluscevic M, Baker DJ, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017;16(10):718-735. PMID: 28729727.
9. He S, Sharpless NE. Senescence in Health and Disease. Cell. 2017;169(6):1000-1011. PMID: 28575665.
10. Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15(7):482-496. PMID: 24954210.
11. Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014;31(6):722-733. PMID: 25499914.
12. Chorev M. The partial retro-inverso modification: a road traveled together. Biopolymers. 2005;80(2-3):67-84. PMID: 15729688.
13. Campisi J. Cell biology: The beginning of the end. Nature. 2014;505(7481):35-36. PMID: 24352243.

Disclaimer — This article is provided strictly for research reference; not for human or veterinary use. FOXO4-DRI is an investigational compound with no regulatory approval. No vendor listed has been assessed or endorsed. Researchers must comply with all applicable institutional, local and national regulations governing peptide acquisition and use.